1-(1H-Indol-3-yl)ethanamine Derivatives as Potent Staphylococcus aureus NorA Efflux Pump Inhibitors

The synthesis of 37 1‐(1H‐indol‐3‐yl)ethanamine derivatives, including 12 new compounds, was achieved through a series of simple and efficient chemical modifications. These indole derivatives displayed modest or no intrinsic anti‐staphylococcal activity. By contrast, several of the compounds restore...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ChemMedChem 2014-07, Vol.9 (7), p.1534-1545
Hauptverfasser: Hequet, Arnaud, Burchak, Olga N., Jeanty, Matthieu, Guinchard, Xavier, Le Pihive, Emmanuelle, Maigre, Laure, Bouhours, Pascale, Schneider, Dominique, Maurin, Max, Paris, Jean-Marc, Denis, Jean-Noël, Jolivalt, Claude
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1545
container_issue 7
container_start_page 1534
container_title ChemMedChem
container_volume 9
creator Hequet, Arnaud
Burchak, Olga N.
Jeanty, Matthieu
Guinchard, Xavier
Le Pihive, Emmanuelle
Maigre, Laure
Bouhours, Pascale
Schneider, Dominique
Maurin, Max
Paris, Jean-Marc
Denis, Jean-Noël
Jolivalt, Claude
description The synthesis of 37 1‐(1H‐indol‐3‐yl)ethanamine derivatives, including 12 new compounds, was achieved through a series of simple and efficient chemical modifications. These indole derivatives displayed modest or no intrinsic anti‐staphylococcal activity. By contrast, several of the compounds restored, in a concentration‐dependent manner, the antibacterial activity of ciprofloxacin against Staphylococcus aureus strains that were resistant to fluoroquinolones due to overexpression of the NorA efflux pump. Structure–activity relationships studies revealed that the indolic aldonitrones halogenated at position 5 of the indole core were the most efficient inhibitors of the S. aureus NorA efflux pump. Among the compounds, (Z)‐N‐benzylidene‐2‐(tert‐butoxycarbonylamino)‐1‐(5‐iodo‐1H‐indol‐3‐yl)ethanamine oxide led to a fourfold decrease of the ciprofloxacin minimum inhibitory concentration against the SA‐1199B strain when used at a concentration of 0.5 mg L−1. To the best of our knowledge, this activity is the highest reported to date for an indolic NorA inhibitor. In addition, a new antibacterial compound, tert‐butyl (2‐(3‐hydroxyureido)‐2‐(1H‐indol‐3‐yl)ethyl)carbamate, which is not toxic for human cells, was also found. A pump turn off: 1‐(1H‐Indol‐3‐yl)ethanamine derivatives such as the one shown here, were synthesized through simple chemical modifications and were shown to be efficient NorA efflux pump inhibitors. They are able to restore ciprofloxacin activity against fluoroquinolone‐resistant Staphylococcus aureus strains.
doi_str_mv 10.1002/cmdc.201400042
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00986364v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1551645567</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5482-fff567c7cdaa768d74c03db243bc8e23327a4c4d006f1eaf343c8c66c2bfc70d3</originalsourceid><addsrcrecordid>eNqNkc1v0zAYxiMEYmNw5YgicdkOLv6K7Ryr7qOVypjEKNwsx7FVjyQudlLW_x5XGRHiAqfX8vt7Hj2vnix7i-AMQYg_6LbWMwwRhRBS_Cw7RYJBwJHgz6c3L0-yVzE-JIIKJF5mJ5gyzjkjp5lG4BwtwaqrfQMIODQXpt-qTrWuM_mlCW6verc3MVcxv_O96fr8c69220Pjtdd6SIshmDRufZjnV9Y2w2N-N7S7fNVtXeV6H-Lr7IVVTTRvnuZZ9uX66n6xBOtPN6vFfA10QQUG1tqCcc11rRRnouZUQ1JXmJJKC4MJwVxRTWsImUVGWUKJFpoxjSurOazJWXYx-m5VI3fBtSocpFdOLudrefyDsBSMMLpHiT0f2V3wPwYTe9m6qE3TqM74IUpUFIjRIgX6D5SmaCUTJKHv_0If_BC6dPSRwpAwhESiZiOlg48xGDuFRVAeW5XHVuXUahK8e7IdqtbUE_67xgSUI_DTNebwDzu5-Hi5-NMcjFoXe_M4aVX4LtPxvJBfb2_ktw1ZXpebe7khvwDDVbte</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1542036118</pqid></control><display><type>article</type><title>1-(1H-Indol-3-yl)ethanamine Derivatives as Potent Staphylococcus aureus NorA Efflux Pump Inhibitors</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Hequet, Arnaud ; Burchak, Olga N. ; Jeanty, Matthieu ; Guinchard, Xavier ; Le Pihive, Emmanuelle ; Maigre, Laure ; Bouhours, Pascale ; Schneider, Dominique ; Maurin, Max ; Paris, Jean-Marc ; Denis, Jean-Noël ; Jolivalt, Claude</creator><creatorcontrib>Hequet, Arnaud ; Burchak, Olga N. ; Jeanty, Matthieu ; Guinchard, Xavier ; Le Pihive, Emmanuelle ; Maigre, Laure ; Bouhours, Pascale ; Schneider, Dominique ; Maurin, Max ; Paris, Jean-Marc ; Denis, Jean-Noël ; Jolivalt, Claude</creatorcontrib><description>The synthesis of 37 1‐(1H‐indol‐3‐yl)ethanamine derivatives, including 12 new compounds, was achieved through a series of simple and efficient chemical modifications. These indole derivatives displayed modest or no intrinsic anti‐staphylococcal activity. By contrast, several of the compounds restored, in a concentration‐dependent manner, the antibacterial activity of ciprofloxacin against Staphylococcus aureus strains that were resistant to fluoroquinolones due to overexpression of the NorA efflux pump. Structure–activity relationships studies revealed that the indolic aldonitrones halogenated at position 5 of the indole core were the most efficient inhibitors of the S. aureus NorA efflux pump. Among the compounds, (Z)‐N‐benzylidene‐2‐(tert‐butoxycarbonylamino)‐1‐(5‐iodo‐1H‐indol‐3‐yl)ethanamine oxide led to a fourfold decrease of the ciprofloxacin minimum inhibitory concentration against the SA‐1199B strain when used at a concentration of 0.5 mg L−1. To the best of our knowledge, this activity is the highest reported to date for an indolic NorA inhibitor. In addition, a new antibacterial compound, tert‐butyl (2‐(3‐hydroxyureido)‐2‐(1H‐indol‐3‐yl)ethyl)carbamate, which is not toxic for human cells, was also found. A pump turn off: 1‐(1H‐Indol‐3‐yl)ethanamine derivatives such as the one shown here, were synthesized through simple chemical modifications and were shown to be efficient NorA efflux pump inhibitors. They are able to restore ciprofloxacin activity against fluoroquinolone‐resistant Staphylococcus aureus strains.</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.201400042</identifier><identifier>PMID: 24677763</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>Amines - chemical synthesis ; Amines - chemistry ; Amines - pharmacology ; Anti-Bacterial Agents - chemical synthesis ; Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - pharmacology ; antibiotics ; Bacterial Proteins - antagonists &amp; inhibitors ; Bacterial Proteins - metabolism ; Biodiversity ; Cell Line ; Cell Proliferation - drug effects ; Ciprofloxacin - pharmacology ; Derivatives ; Drug Resistance, Bacterial - drug effects ; efflux pumps ; Humans ; indoles ; Indoles - chemistry ; inhibitors ; Life Sciences ; Medical research ; Microbial Sensitivity Tests ; Multidrug Resistance-Associated Proteins - antagonists &amp; inhibitors ; Multidrug Resistance-Associated Proteins - metabolism ; Penicillin ; Populations and Evolution ; Staphylococcus aureus ; Staphylococcus aureus - drug effects ; Staphylococcus aureus - metabolism ; Structure-Activity Relationship ; structure-activity relationships</subject><ispartof>ChemMedChem, 2014-07, Vol.9 (7), p.1534-1545</ispartof><rights>2014 WILEY‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><rights>2014 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</rights><rights>2014 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5482-fff567c7cdaa768d74c03db243bc8e23327a4c4d006f1eaf343c8c66c2bfc70d3</citedby><cites>FETCH-LOGICAL-c5482-fff567c7cdaa768d74c03db243bc8e23327a4c4d006f1eaf343c8c66c2bfc70d3</cites><orcidid>0000-0003-2353-8236</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcmdc.201400042$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcmdc.201400042$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24677763$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00986364$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Hequet, Arnaud</creatorcontrib><creatorcontrib>Burchak, Olga N.</creatorcontrib><creatorcontrib>Jeanty, Matthieu</creatorcontrib><creatorcontrib>Guinchard, Xavier</creatorcontrib><creatorcontrib>Le Pihive, Emmanuelle</creatorcontrib><creatorcontrib>Maigre, Laure</creatorcontrib><creatorcontrib>Bouhours, Pascale</creatorcontrib><creatorcontrib>Schneider, Dominique</creatorcontrib><creatorcontrib>Maurin, Max</creatorcontrib><creatorcontrib>Paris, Jean-Marc</creatorcontrib><creatorcontrib>Denis, Jean-Noël</creatorcontrib><creatorcontrib>Jolivalt, Claude</creatorcontrib><title>1-(1H-Indol-3-yl)ethanamine Derivatives as Potent Staphylococcus aureus NorA Efflux Pump Inhibitors</title><title>ChemMedChem</title><addtitle>ChemMedChem</addtitle><description>The synthesis of 37 1‐(1H‐indol‐3‐yl)ethanamine derivatives, including 12 new compounds, was achieved through a series of simple and efficient chemical modifications. These indole derivatives displayed modest or no intrinsic anti‐staphylococcal activity. By contrast, several of the compounds restored, in a concentration‐dependent manner, the antibacterial activity of ciprofloxacin against Staphylococcus aureus strains that were resistant to fluoroquinolones due to overexpression of the NorA efflux pump. Structure–activity relationships studies revealed that the indolic aldonitrones halogenated at position 5 of the indole core were the most efficient inhibitors of the S. aureus NorA efflux pump. Among the compounds, (Z)‐N‐benzylidene‐2‐(tert‐butoxycarbonylamino)‐1‐(5‐iodo‐1H‐indol‐3‐yl)ethanamine oxide led to a fourfold decrease of the ciprofloxacin minimum inhibitory concentration against the SA‐1199B strain when used at a concentration of 0.5 mg L−1. To the best of our knowledge, this activity is the highest reported to date for an indolic NorA inhibitor. In addition, a new antibacterial compound, tert‐butyl (2‐(3‐hydroxyureido)‐2‐(1H‐indol‐3‐yl)ethyl)carbamate, which is not toxic for human cells, was also found. A pump turn off: 1‐(1H‐Indol‐3‐yl)ethanamine derivatives such as the one shown here, were synthesized through simple chemical modifications and were shown to be efficient NorA efflux pump inhibitors. They are able to restore ciprofloxacin activity against fluoroquinolone‐resistant Staphylococcus aureus strains.</description><subject>Amines - chemical synthesis</subject><subject>Amines - chemistry</subject><subject>Amines - pharmacology</subject><subject>Anti-Bacterial Agents - chemical synthesis</subject><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>antibiotics</subject><subject>Bacterial Proteins - antagonists &amp; inhibitors</subject><subject>Bacterial Proteins - metabolism</subject><subject>Biodiversity</subject><subject>Cell Line</subject><subject>Cell Proliferation - drug effects</subject><subject>Ciprofloxacin - pharmacology</subject><subject>Derivatives</subject><subject>Drug Resistance, Bacterial - drug effects</subject><subject>efflux pumps</subject><subject>Humans</subject><subject>indoles</subject><subject>Indoles - chemistry</subject><subject>inhibitors</subject><subject>Life Sciences</subject><subject>Medical research</subject><subject>Microbial Sensitivity Tests</subject><subject>Multidrug Resistance-Associated Proteins - antagonists &amp; inhibitors</subject><subject>Multidrug Resistance-Associated Proteins - metabolism</subject><subject>Penicillin</subject><subject>Populations and Evolution</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus aureus - metabolism</subject><subject>Structure-Activity Relationship</subject><subject>structure-activity relationships</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1v0zAYxiMEYmNw5YgicdkOLv6K7Ryr7qOVypjEKNwsx7FVjyQudlLW_x5XGRHiAqfX8vt7Hj2vnix7i-AMQYg_6LbWMwwRhRBS_Cw7RYJBwJHgz6c3L0-yVzE-JIIKJF5mJ5gyzjkjp5lG4BwtwaqrfQMIODQXpt-qTrWuM_mlCW6verc3MVcxv_O96fr8c69220Pjtdd6SIshmDRufZjnV9Y2w2N-N7S7fNVtXeV6H-Lr7IVVTTRvnuZZ9uX66n6xBOtPN6vFfA10QQUG1tqCcc11rRRnouZUQ1JXmJJKC4MJwVxRTWsImUVGWUKJFpoxjSurOazJWXYx-m5VI3fBtSocpFdOLudrefyDsBSMMLpHiT0f2V3wPwYTe9m6qE3TqM74IUpUFIjRIgX6D5SmaCUTJKHv_0If_BC6dPSRwpAwhESiZiOlg48xGDuFRVAeW5XHVuXUahK8e7IdqtbUE_67xgSUI_DTNebwDzu5-Hi5-NMcjFoXe_M4aVX4LtPxvJBfb2_ktw1ZXpebe7khvwDDVbte</recordid><startdate>201407</startdate><enddate>201407</enddate><creator>Hequet, Arnaud</creator><creator>Burchak, Olga N.</creator><creator>Jeanty, Matthieu</creator><creator>Guinchard, Xavier</creator><creator>Le Pihive, Emmanuelle</creator><creator>Maigre, Laure</creator><creator>Bouhours, Pascale</creator><creator>Schneider, Dominique</creator><creator>Maurin, Max</creator><creator>Paris, Jean-Marc</creator><creator>Denis, Jean-Noël</creator><creator>Jolivalt, Claude</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><general>Wiley Subscription Services, Inc</general><general>Wiley-VCH Verlag</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>7QL</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-2353-8236</orcidid></search><sort><creationdate>201407</creationdate><title>1-(1H-Indol-3-yl)ethanamine Derivatives as Potent Staphylococcus aureus NorA Efflux Pump Inhibitors</title><author>Hequet, Arnaud ; Burchak, Olga N. ; Jeanty, Matthieu ; Guinchard, Xavier ; Le Pihive, Emmanuelle ; Maigre, Laure ; Bouhours, Pascale ; Schneider, Dominique ; Maurin, Max ; Paris, Jean-Marc ; Denis, Jean-Noël ; Jolivalt, Claude</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5482-fff567c7cdaa768d74c03db243bc8e23327a4c4d006f1eaf343c8c66c2bfc70d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Amines - chemical synthesis</topic><topic>Amines - chemistry</topic><topic>Amines - pharmacology</topic><topic>Anti-Bacterial Agents - chemical synthesis</topic><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>antibiotics</topic><topic>Bacterial Proteins - antagonists &amp; inhibitors</topic><topic>Bacterial Proteins - metabolism</topic><topic>Biodiversity</topic><topic>Cell Line</topic><topic>Cell Proliferation - drug effects</topic><topic>Ciprofloxacin - pharmacology</topic><topic>Derivatives</topic><topic>Drug Resistance, Bacterial - drug effects</topic><topic>efflux pumps</topic><topic>Humans</topic><topic>indoles</topic><topic>Indoles - chemistry</topic><topic>inhibitors</topic><topic>Life Sciences</topic><topic>Medical research</topic><topic>Microbial Sensitivity Tests</topic><topic>Multidrug Resistance-Associated Proteins - antagonists &amp; inhibitors</topic><topic>Multidrug Resistance-Associated Proteins - metabolism</topic><topic>Penicillin</topic><topic>Populations and Evolution</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus aureus - metabolism</topic><topic>Structure-Activity Relationship</topic><topic>structure-activity relationships</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hequet, Arnaud</creatorcontrib><creatorcontrib>Burchak, Olga N.</creatorcontrib><creatorcontrib>Jeanty, Matthieu</creatorcontrib><creatorcontrib>Guinchard, Xavier</creatorcontrib><creatorcontrib>Le Pihive, Emmanuelle</creatorcontrib><creatorcontrib>Maigre, Laure</creatorcontrib><creatorcontrib>Bouhours, Pascale</creatorcontrib><creatorcontrib>Schneider, Dominique</creatorcontrib><creatorcontrib>Maurin, Max</creatorcontrib><creatorcontrib>Paris, Jean-Marc</creatorcontrib><creatorcontrib>Denis, Jean-Noël</creatorcontrib><creatorcontrib>Jolivalt, Claude</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hequet, Arnaud</au><au>Burchak, Olga N.</au><au>Jeanty, Matthieu</au><au>Guinchard, Xavier</au><au>Le Pihive, Emmanuelle</au><au>Maigre, Laure</au><au>Bouhours, Pascale</au><au>Schneider, Dominique</au><au>Maurin, Max</au><au>Paris, Jean-Marc</au><au>Denis, Jean-Noël</au><au>Jolivalt, Claude</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1-(1H-Indol-3-yl)ethanamine Derivatives as Potent Staphylococcus aureus NorA Efflux Pump Inhibitors</atitle><jtitle>ChemMedChem</jtitle><addtitle>ChemMedChem</addtitle><date>2014-07</date><risdate>2014</risdate><volume>9</volume><issue>7</issue><spage>1534</spage><epage>1545</epage><pages>1534-1545</pages><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>The synthesis of 37 1‐(1H‐indol‐3‐yl)ethanamine derivatives, including 12 new compounds, was achieved through a series of simple and efficient chemical modifications. These indole derivatives displayed modest or no intrinsic anti‐staphylococcal activity. By contrast, several of the compounds restored, in a concentration‐dependent manner, the antibacterial activity of ciprofloxacin against Staphylococcus aureus strains that were resistant to fluoroquinolones due to overexpression of the NorA efflux pump. Structure–activity relationships studies revealed that the indolic aldonitrones halogenated at position 5 of the indole core were the most efficient inhibitors of the S. aureus NorA efflux pump. Among the compounds, (Z)‐N‐benzylidene‐2‐(tert‐butoxycarbonylamino)‐1‐(5‐iodo‐1H‐indol‐3‐yl)ethanamine oxide led to a fourfold decrease of the ciprofloxacin minimum inhibitory concentration against the SA‐1199B strain when used at a concentration of 0.5 mg L−1. To the best of our knowledge, this activity is the highest reported to date for an indolic NorA inhibitor. In addition, a new antibacterial compound, tert‐butyl (2‐(3‐hydroxyureido)‐2‐(1H‐indol‐3‐yl)ethyl)carbamate, which is not toxic for human cells, was also found. A pump turn off: 1‐(1H‐Indol‐3‐yl)ethanamine derivatives such as the one shown here, were synthesized through simple chemical modifications and were shown to be efficient NorA efflux pump inhibitors. They are able to restore ciprofloxacin activity against fluoroquinolone‐resistant Staphylococcus aureus strains.</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>24677763</pmid><doi>10.1002/cmdc.201400042</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-2353-8236</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1860-7179
ispartof ChemMedChem, 2014-07, Vol.9 (7), p.1534-1545
issn 1860-7179
1860-7187
language eng
recordid cdi_hal_primary_oai_HAL_hal_00986364v1
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Amines - chemical synthesis
Amines - chemistry
Amines - pharmacology
Anti-Bacterial Agents - chemical synthesis
Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - pharmacology
antibiotics
Bacterial Proteins - antagonists & inhibitors
Bacterial Proteins - metabolism
Biodiversity
Cell Line
Cell Proliferation - drug effects
Ciprofloxacin - pharmacology
Derivatives
Drug Resistance, Bacterial - drug effects
efflux pumps
Humans
indoles
Indoles - chemistry
inhibitors
Life Sciences
Medical research
Microbial Sensitivity Tests
Multidrug Resistance-Associated Proteins - antagonists & inhibitors
Multidrug Resistance-Associated Proteins - metabolism
Penicillin
Populations and Evolution
Staphylococcus aureus
Staphylococcus aureus - drug effects
Staphylococcus aureus - metabolism
Structure-Activity Relationship
structure-activity relationships
title 1-(1H-Indol-3-yl)ethanamine Derivatives as Potent Staphylococcus aureus NorA Efflux Pump Inhibitors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T04%3A55%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1-(1H-Indol-3-yl)ethanamine%20Derivatives%20as%20Potent%20Staphylococcus%20aureus%20NorA%20Efflux%20Pump%20Inhibitors&rft.jtitle=ChemMedChem&rft.au=Hequet,%20Arnaud&rft.date=2014-07&rft.volume=9&rft.issue=7&rft.spage=1534&rft.epage=1545&rft.pages=1534-1545&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.201400042&rft_dat=%3Cproquest_hal_p%3E1551645567%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1542036118&rft_id=info:pmid/24677763&rfr_iscdi=true